Henry Schein (NASDAQ:HSIC) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Thursday, January 4th.

According to Zacks, “Over the past three months, Henry Schein has underperformed the broader industry. The company witnessing year-over-year deterioration in gross and operating margin due to higher cost of sales and expenses continues to be a concern. This apart, competitive pricing remains another cause of concern. We are disappointed with the company’s lowering of the high end of the 2017 EPS guidance indicating a gloomy scenario ahead. On a positive note, balanced growth across all operating segments as well as the Henry Schein’s gains in the United States as well as overseas raise optimism. We are also positive about the company completing the buyout of Merritt Veterinary Supplies.”

How to Become a New Pot Stock Millionaire

A number of other equities research analysts have also commented on the company. Morgan Stanley lowered Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price target for the company. in a research report on Wednesday, December 6th. Piper Jaffray Companies raised Henry Schein from a “neutral” rating to an “overweight” rating in a research report on Friday, September 15th. Craig Hallum raised Henry Schein from a “hold” rating to a “buy” rating in a research report on Tuesday, November 7th. Credit Suisse Group reaffirmed a “neutral” rating and set a $80.00 target price (down from $87.50) on shares of Henry Schein in a research report on Tuesday, November 28th. Finally, Jefferies Group cut their price target on Henry Schein from $89.00 to $74.00 and set a “hold” rating for the company in a research note on Tuesday, November 7th. Two analysts have rated the stock with a sell rating, seven have given a hold rating and eight have issued a buy rating to the company. Henry Schein presently has a consensus rating of “Hold” and an average price target of $84.23.

Shares of Henry Schein (HSIC) traded down $0.55 during trading hours on Thursday, hitting $78.86. The stock had a trading volume of 706,488 shares, compared to its average volume of 1,449,771. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. Henry Schein has a one year low of $65.28 and a one year high of $93.50. The firm has a market capitalization of $12,388.41, a price-to-earnings ratio of 22.68, a price-to-earnings-growth ratio of 2.02 and a beta of 1.00.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Monday, November 6th. The company reported $0.87 earnings per share for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. Henry Schein’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the previous year, the company earned $0.84 earnings per share. research analysts anticipate that Henry Schein will post 3.6 EPS for the current year.

In other news, Director Barry J. Alperin sold 5,796 shares of Henry Schein stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $70.76, for a total transaction of $410,124.96. Following the completion of the sale, the director now owns 48,172 shares in the company, valued at approximately $3,408,650.72. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.19% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of HSIC. BTIM Corp. increased its stake in Henry Schein by 6,807.6% in the 4th quarter. BTIM Corp. now owns 196,868 shares of the company’s stock worth $13,757,000 after purchasing an additional 194,018 shares during the period. PGGM Investments increased its stake in Henry Schein by 46.1% in the 4th quarter. PGGM Investments now owns 520,800 shares of the company’s stock worth $36,394,000 after purchasing an additional 164,440 shares during the period. Meag Munich Ergo Kapitalanlagegesellschaft MBH purchased a new position in Henry Schein in the 4th quarter worth approximately $2,659,000. K.J. Harrison & Partners Inc purchased a new position in Henry Schein in the 4th quarter worth approximately $760,000. Finally, Commerzbank Aktiengesellschaft FI increased its stake in Henry Schein by 1,012.3% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 33,148 shares of the company’s stock worth $2,316,000 after purchasing an additional 30,168 shares during the period. Hedge funds and other institutional investors own 91.10% of the company’s stock.

WARNING: “Henry Schein (NASDAQ:HSIC) Upgraded at Zacks Investment Research” was published by Marea Informative and is owned by of Marea Informative. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/30/henry-schein-hsic-raised-to-hold-at-zacks-investment-research-updated-updated-updated.html.

About Henry Schein

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Get a free copy of the Zacks research report on Henry Schein (HSIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.